ClinicalTrials.gg
CompletedNCT03432533Updated Nov 23, 2020Results posted

A Comparison of Subject-administered Romosozumab With Healthcare Provider-administered Romosozumab for Osteoporosis

A Phase 3 interventional study of romosozumab HCP administration with PFS and romosozumab self-administration with AI/Pen in Post-Menopausal Osteoporosis, sponsored by Amgen. Completed at 46 sites in 3 countries. Open to female participants aged 55 Years to 90 Years. Per ClinicalTrials.gov, last updated 2020-11-23.

Sponsored by Amgen · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
283
Allocation
Randomized
Ages
55 Years to 90 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 12 studies testing romosozumab in Osteoporosis, Postmenopausal — 1 open to participants now, 2 under way, none of them phase 3. romosozumab · Osteoporosis, Postmenopausal.

Enrollment
6th of 12
283 · median 268
Started
2018
the only one that year
Phase 3
6 of 12
none open now
Registered
8th of 12
by date
Lead sponsor
9 of 12
Amgen

Among the 12 studies testing romosozumab in Osteoporosis, Postmenopausal, this one is the 6th largest by enrollment, is the only one that started in 2018, is one of 6 in phase 3, and was the 8th registered.

Osteoporosis, Postmenopausal

334 studies on the registry are indexed under Osteoporosis, Postmenopausal; 28 are open to participants now.

Browse Osteoporosis, Postmenopausal studies →

Open to participants now

1 of the 12 studies testing romosozumab in Osteoporosis, Postmenopausal is open now. Recruiting first, the newest first:

About romosozumab

romosozumab: first FDA approval 2019 (EVENITY), first EMA approval 2019. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 19 Osteoporosis, Postmenopausal studies recruiting now, 8 (42%) set no upper age limit and 7 (37%) stop at 75 or younger; 1 takes children under 18; 7 take healthy volunteers.

This study: 55 Years to 90 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies testing romosozumab in Osteoporosis, Postmenopausal, or all of them as a file.
02

Study summary

To evaluate the noninferiority of a 6-month treatment with 210 mg romosozumab at 90 mg/mL administered subcutaneously (SC) once a month (QM) in postmenopausal women with osteoporosis either by healthcare provider (HCP) administration with prefilled syringe (PFS) or by subject self-administration with autoinjector/pen (AI/Pen)

03

Conditions studied

  • Post-Menopausal Osteoporosis

Keywords

  • Post-Menopausal osteoporosis
04

Who can participate

Ages eligible
55 Years to 90 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subject has provided /assent prior to initiation of any studyspecific activities/procedures, or subject's legally acceptable representative has provided informed consent prior to any study-specific activities/procedures being initiated when the subject has any kind of condition that, in the opinion of the Investigator, may compromise the ability of the subject to give written informed consent.
  • female (postmenopausal status is defined as no vaginal bleeding or spotting for 12 consecutive months prior to screening)

    -≥ 55 to ≤ 90 years of age at the time of informed consent

  • Ambulatory
  • BMD T-score ≤ -2.50 at the lumbar spine, total hip, or femoral neck, as assessed by the central imaging vendor at the time of screening, based on DXA scans -Subject has at least 2 vertebrae in the L1-L4 region evaluable by DXA, as assessed by the principal investigator or designee
  • Subject has at least 1 hip evaluable by DXA, as assessed by the principal investigator or designee
  • Subject has history of fragility (ie, osteoporosis-related fracture) or subject meets at least 2 of the following clinical risk factors for fracture

    • ≥ 70 years of age at the time of informed consent
    • BMD T-score ≤ -3.00 at the lumbar spine, total hip, or femoral neck, as assessed by the central imaging vendor at the time of screening, based on DXA scans
    • current smoker
    • consumption of ≥ 3 glasses of alcohol a day
    • parental history of fragility (ie, osteoporosis-related) fracture
    • body weight ≤ 125 pounds/56 kilogram
  • Ability to follow and understand instructions and the ability to self-inject, per investigator judgement

Exclusion criteria

Exclusion Criteria:

  • History of osteonecrosis of the jaw and/or atypical femoral fracture
  • History of metabolic or bone disease (except osteoporosis) that may interfere with the interpretation of the results, such as sclerosteosis, Paget's disease, rheumatoid arthritis, osteomalacia, osteogenesis imperfecta, osteopetrosis, ankylosing spondylitis, Cushing's disease, hyperprolactinemia, and malabsorption syndrome
  • Subject with reported history of hearing loss associated with cranial nerve VIII compression due to excessive bone growth (eg, as seen in conditions such as Paget's disease, sclerosteosis and osteopetrosis)
  • Vitamin D insufficiency [defined as serum 25 (OH) vitamin D levels \< 20 ng/mL], as determined by the central laboratory. Vitamin D repletion will be permitted a nd subjects may be rescreened
  • Current hyperthyroidism (unless well controlled on stable antithyroid therapy) by subject report or by chart review, per principal investigator evaluation
  • Current clinical hypothyroidism (unless well controlled on stable thyroid replacement therapy) by subject report or by chart review, per principal investigator evaluation normal range, per subject medical history. Uncontrolled hyperparathyroidism is defined as: parathyroid hormone (PTH) outside the normal range in subjects with concurrent hypercalcemia; or PTH values > 20% above the (ULN) in normocalcemic subjects.
  • Current hyper- or hypocalcemia, defined as albumin-adjusted serum calcium outside the normal range, as assessed by the central laboratory. Serum calcium levels may be retested once in case of an elevated serum calcium level within 1.1x the ULN as assessed by the central laboratory
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
283 participants (actual)

Study arms

  • Active comparator
    Romosozumab 210 mg QM: PFS

    During the open-label treatment period, participants receive 210 mg romosozumab SC QM by HCP administration with PFS.

    Drug: romosozumab HCP administration with PFS

  • Active comparator
    Romosozumab 210 mg QM: AI/Pen

    During the open-label treatment period, participants receive 210 mg romosozumab SC QM by self-administration with AI/pen.

    Device: romosozumab self-administration with AI/Pen

Interventions

  • Drugromosozumab HCP administration with PFS

    Drug page: Romosozumab

    210 mg romosozumab SC QM by HCP administration with 2 PFS

    Also known as: Evenity, AMG785

  • Deviceromosozumab self-administration with AI/Pen

    210 mg romosozumab SC QM by self-administration with 2 AI/Pens

    Also known as: Evenity, AMG785

06

What researchers measure

Primary outcomes

  1. Percent Change From Baseline in Lumbar Spine BMD at Month 6

    Percent change from baseline in BMD at the lumbar spine as measured by dual-energy x-ray absorptiometry (DXA).

    Time frame: Baseline, Month 6

Secondary outcomes

  1. Percent Change From Baseline in Total Hip BMD at Month 6

    Percent change from baseline in BMD for total hip as measured by DXA.

    Time frame: Baseline, Month 6

  2. Percent Change From Baseline in Femoral Neck BMD at Month 6

    Percent change from baseline in BMD at femoral neck as measured by DXA.

    Time frame: Baseline, Month 6

  3. Number of Participants With Treatment Emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs), Device-Related AEs, Discontinuations Due to AEs, and Deaths

    AE: any untoward medical occurrence irrespective of a causal relationship with the study treatment. SAE: any untoward medical occurrence that meets at least 1 of the following criteria: results in death; is immediately life-threatening; requires in-patient hospitalization or prolongation of existing hospitalization; results in persistent or significant disability/incapacity; is a congenital anomaly/birth defect; is a medically important serious event. Adverse device effect: any AE related to the use of a combination product or medical device. TEAEs are those AEs occurring after first dose of study drug.

    Time frame: up to Month 9 (-7/+3 days)

  4. Number of Participants Developing Anti-Romosozumab Antibodies

    Participants with a negative or no result at baseline (BL) developing anti-romosozumab antibodies postbaseline, including those who were binding antibody-positive or neutralizing antibody-positive postbaseline. 'Transient' positive results are those with a negative result at the participant's last time point tested within the study period.

    Time frame: up to Month 9 (-7/+3 days)

07

Results

Posted Apr 10, 2020

Participant flow

Participants were enrolled at 36 centers in Poland, United Kingdom, and United States.

Participant flow — Overall Study
MilestoneRomosozumab 210 mg QM: PFSRomosozumab 210 mg QM: AI/Pen
Started141142
Completed 6-month treatment period136137
Completed126131
Not completed1511
Withdrew: Lost to follow-up12
Withdrew: Withdrawal by subject149

Outcome measures

PrimaryPercent Change From Baseline in Lumbar Spine BMD at Month 6

Percent change from baseline in BMD at the lumbar spine as measured by dual-energy x-ray absorptiometry (DXA).

Time frame:
Baseline, Month 6
Reported as:
Least squares mean · percent change
Percent Change From Baseline in Lumbar Spine BMD at Month 6
percent changeRomosozumab 210 mg QM: PFSRomosozumab 210 mg QM: AI/Pen
Percent Change From Baseline in Lumbar Spine BMD at Month 69.2 ± 0.49.0 ± 0.5
Statistical analysis
  • Romosozumab 210 mg QM: PFS vs Romosozumab 210 mg QM: AI/Pen · ANCOVA · p = 0.84 · Ls mean difference: -0.1 · 95% CI -1.3 to 1.0
SecondaryPercent Change From Baseline in Total Hip BMD at Month 6

Percent change from baseline in BMD for total hip as measured by DXA.

Time frame:
Baseline, Month 6
Reported as:
Least squares mean · percent change
Percent Change From Baseline in Total Hip BMD at Month 6
percent changeRomosozumab 210 mg QM: PFSRomosozumab 210 mg QM: AI/Pen
Percent Change From Baseline in Total Hip BMD at Month 63.7 ± 0.63.6 ± 0.3
SecondaryPercent Change From Baseline in Femoral Neck BMD at Month 6

Percent change from baseline in BMD at femoral neck as measured by DXA.

Time frame:
Baseline, Month 6
Reported as:
Least squares mean · percent change
Percent Change From Baseline in Femoral Neck BMD at Month 6
percent changeRomosozumab 210 mg QM: PFSRomosozumab 210 mg QM: AI/Pen
Percent Change From Baseline in Femoral Neck BMD at Month 63.4 ± 0.73.6 ± 0.5
SecondaryNumber of Participants With Treatment Emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs), Device-Related AEs, Discontinuations Due to AEs, and Deaths

AE: any untoward medical occurrence irrespective of a causal relationship with the study treatment. SAE: any untoward medical occurrence that meets at least 1 of the following criteria: results in death; is immediately life-threatening; requires in-patient hospitalization or prolongation of existing hospitalization; results in persistent or significant disability/incapacity; is a congenital anomaly/birth defect; is a medically important serious event. Adverse device effect: any AE related to the use of a combination product or medical device. TEAEs are those AEs occurring after first dose of study drug.

Time frame:
up to Month 9 (-7/+3 days)
Reported as:
Number · participants
Number of Participants With Treatment Emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs), Device-Related AEs, Discontinuations Due to AEs, and Deaths
participantsRomosozumab 210 mg QM: PFSRomosozumab 210 mg QM: AI/Pen
TEAEs: All9496
TEAEs: SAEs74
TEAEs: Leading to Study Drug Discontinuation (DC)715
TEAEs: Fatal00
Treatment-Related (TR) TEAEs: All3859
TR TEAEs: SAEs00
TR TEAEs: Leading to Study Drug DC610
TR TEAEs: Fatal00
Device-Related (DR) TEAEs: All1830
DR TEAEs: SAEs00
DR TEAEs: Leading to Study Drug DC05
DR TEAEs: Fatal00
SecondaryNumber of Participants Developing Anti-Romosozumab Antibodies

Participants with a negative or no result at baseline (BL) developing anti-romosozumab antibodies postbaseline, including those who were binding antibody-positive or neutralizing antibody-positive postbaseline. 'Transient' positive results are those with a negative result at the participant's last time point tested within the study period.

Time frame:
up to Month 9 (-7/+3 days)
Reported as:
Count of participants · Participants
Number of Participants Developing Anti-Romosozumab Antibodies
ParticipantsRomosozumab 210 mg QM: PFSRomosozumab 210 mg QM: AI/Pen
Binding Antibody Positive Post-BL2122
Transient Binding Antibody Positive Post-BL63
Neutralizing Antibody Positive Post-BL54
Transient Neutralizing Antibody Positive Post-BL02

Adverse events

Collected over up to Month 9 (-7/+3 days). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Romosozumab 210 mg SC QM by PFS0/141 (0%)7/141 (5%)48/141 (34%)
Romosozumab 210 mg SC QM by AI/Pen0/142 (0%)4/142 (2.8%)64/142 (45.1%)
Most frequent serious events
Showing 10 of 13
Most frequent serious events
EventRomosozumab 210 mg SC QM by PFSRomosozumab 210 mg SC QM by AI/Pen
Colitis ischaemicGastrointestinal disorders1/1410/142
CellulitisInfections and infestations1/1410/142
Clostridium difficile infectionInfections and infestations1/1410/142
Urinary tract infectionInfections and infestations1/1410/142
Forearm fractureInjury, poisoning and procedural complications1/1410/142
Humerus fractureInjury, poisoning and procedural complications1/1410/142
Basal cell carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/1410/142
GlioblastomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/1410/142
Cerebrovascular accidentNervous system disorders1/1410/142
Deep vein thrombosisVascular disorders1/1411/142
Most frequent other events
Most frequent other events
EventRomosozumab 210 mg SC QM by PFSRomosozumab 210 mg SC QM by AI/Pen
Injection site erythemaGeneral disorders25/14135/142
Injection site swellingGeneral disorders11/14123/142
Injection site painGeneral disorders14/14121/142
NasopharyngitisInfections and infestations15/14110/142
ArthralgiaMusculoskeletal and connective tissue disorders7/1419/142
HeadacheNervous system disorders3/1419/142
Upper respiratory tract infectionInfections and infestations2/1418/142

Baseline characteristics

Age, Continuous
Age, Continuous(years)Romosozumab 210 mg QM: PFSRomosozumab 210 mg QM: AI/PenTotal
Mean70.3 ± 7.169.5 ± 8.469.9 ± 7.8
Sex: Female, Male
Sex: Female, Male(Participants)Romosozumab 210 mg QM: PFSRomosozumab 210 mg QM: AI/PenTotal
Female141142283
Male000
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Romosozumab 210 mg QM: PFSRomosozumab 210 mg QM: AI/PenTotal
Hispanic or Latino314
Not Hispanic or Latino138141279
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Romosozumab 210 mg QM: PFSRomosozumab 210 mg QM: AI/PenTotal
American Indian or Alaska Native000
Asian112
Native Hawaiian or Other Pacific Islander000
Black or African American112
White139140279
More than one race000
Unknown or Not Reported000
Lumbar Spine Bone Mineral Density (BMD) T-Score
Lumbar Spine Bone Mineral Density (BMD) T-Score(T-score)Romosozumab 210 mg QM: PFSRomosozumab 210 mg QM: AI/PenTotal
Mean-2.69 ± 1.03-2.85 ± 1.00-2.77 ± 1.02
Total Hip BMD T-Score
Total Hip BMD T-Score(T-score)Romosozumab 210 mg QM: PFSRomosozumab 210 mg QM: AI/PenTotal
Mean-2.29 ± 0.73-2.30 ± 0.77-2.29 ± 0.75
Femoral Neck BMD T-Score
Femoral Neck BMD T-Score(T-score)Romosozumab 210 mg QM: PFSRomosozumab 210 mg QM: AI/PenTotal
Mean-2.54 ± 0.63-2.49 ± 0.65-2.52 ± 0.64
Participants With Pre-Existing Anti-Romosozumab Antibodies
Participants With Pre-Existing Anti-Romosozumab Antibodies(Participants)Romosozumab 210 mg QM: PFSRomosozumab 210 mg QM: AI/PenTotal
Binding Antibody Positive at or Before BL303
Neutralizing Antibody Positive at or Before BL000
08

Study locations

46 sites
  • Research Site
    Birmingham, Alabama 35205, United States
  • Research Site
    Birmingham, Alabama 35294, United States
  • Research Site
    Huntsville, Alabama 35801, United States
  • Research Site
    Tuscaloosa, Alabama 35406, United States
  • Research Site
    Chandler, Arizona 85224, United States
  • Research Site
    Mesa, Arizona 85213, United States
  • Research Site
    Cypress, California 90630, United States
  • Research Site
    Fullerton, California 92835, United States
  • Research Site
    Glendale, California 91206, United States
  • Research Site
    Laguna Hills, California 92653, United States
  • Research Site
    Santa Maria, California 93454, United States
  • Research Site
    Tustin, California 92780, United States
  • Research Site
    Denver, Colorado 80230, United States
  • Research Site
    Golden, Colorado 80401, United States
  • Research Site
    Delray Beach, Florida 33446, United States
  • Research Site
    South Miami, Florida 33143, United States
  • Research Site
    Atlanta, Georgia 30319, United States
  • Research Site
    Atlanta, Georgia 30342, United States
  • Research Site
    Bridgeton, Missouri 63044, United States
  • Research Site
    Springfield, Missouri 65802, United States
  • Research Site
    Las Vegas, Nevada 89148, United States
  • Research Site
    Great Neck, New York 11021, United States
  • Research Site
    Charlotte, North Carolina 28204, United States
  • Research Site
    Fargo, North Dakota 58103, United States
  • Research Site
    Cincinnati, Ohio 45242, United States
  • Research Site
    Duncansville, Pennsylvania 16635, United States
  • Research Site
    Wyomissing, Pennsylvania 19610, United States
  • Research Site
    Spartanburg, South Carolina 29303, United States
  • Research Site
    Summerville, South Carolina 29486, United States
  • Research Site
    San Antonio, Texas 78209, United States
  • Research Site
    Salt Lake City, Utah 84107, United States
  • Research Site
    Chesapeake, Virginia 23320, United States
  • Research Site
    Danville, Virginia 24541, United States
  • Research Site
    Renton, Washington 98057, United States
  • Research Site
    Franklin, Wisconsin 53132, United States
  • Research Site
    Bialystok, 15-351, Poland
  • Research Site
    Lodz, 90-558, Poland
  • Research Site
    Swidnik, 21-040, Poland
  • Research Site
    Warszawa, 01-192, Poland
  • Research Site
    Chorley, PR7 7NA, United Kingdom
  • Research Site
    Edinburgh, EH4 2XU, United Kingdom
  • Research Site
    Liverpool, L22 0LG, United Kingdom
  • Research Site
    London, DA14 6LT, United Kingdom
  • Research Site
    Manchester, M15 6SX, United Kingdom
  • Research Site
    Northwood, HA6 2RN, United Kingdom
  • Research Site
    Romford, RM1 3PJ, United Kingdom
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — De-identified individual patient data for variables necessary to address the specific research question in an approved data sharing request.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: Data sharing requests relating to this study will be considered beginning 18 months after the study has ended and either 1) the product and indication (or other new use) have been granted marketing authorization in both the US and Europe or 2) clinical development for the product and/or indication discontinues and the data will not be submitted to regulatory authorities. There is no end date for eligibility to submit a data sharing request for this study.

Access criteria: Qualified researchers may submit a request containing the research objectives, the Amgen product(s) and Amgen study/studies in scope, endpoints/outcomes of interest, statistical analysis plan, data requirements, publication plan, and qualifications of the researcher(s). In general, Amgen does not grant external requests for individual patient data for the purpose of re-evaluating safety and efficacy issues already addressed in the product labelling. Requests are reviewed by a committee of internal advisors, and if not approved, may be further arbitrated by a Data Sharing Independent Review Panel. Upon approval, information necessary to address the research question will be provided under the terms of a data sharing agreement. This may include anonymized individual patient data and/or available supporting documents, containing fragments of analysis code where provided in analysis specifications. Further details are available at the link below.

Data sharing details ↗ · www.amgen.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2018 to primary completion in Apr 2019, 14 months.

Results were first posted in Apr 2020, 11 months after primary completion.

Of 29 industry-sponsored phase 3 interventional studies under Osteoporosis, Postmenopausal, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 43. This study's 14 months is below that.

Counting every sponsor, half of 30 studies reached it within 24 months; a quarter within 20 and three quarters within 44.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 30, 2018
First posted
Feb 14, 2018
StartActual
Feb 6, 2018
Primary completionActual
Apr 11, 2019
CompletionActual
Jan 8, 2020
Results first posted
Apr 10, 2020
Last update
Nov 23, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 23, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03432533
Lead sponsor
Amgen
Responsible party
Sponsor
First posted
Feb 14, 2018
Start date
Feb 6, 2018
Primary completion
Apr 11, 2019
Completion
Jan 8, 2020
Results posted
Apr 10, 2020
Last update
Nov 23, 2020

Study contacts

MD
study director · Amgen

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Romosozumab

Start the discussion